A phase II trial of IDO-inhibitor, BMS-986205 (IDO), and PD-1 inhibitor, nivolumab (NIVO), in recurrent or persistent endometrial cancer (EC; CA017-056).
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Chrisann Kyi, Maria M Rubinstein, Pooja Shah, Qin Zhou, Alexia Iasonos, Yue Liu, Lizbeth Ramirez, Viktoriya Paroder, Angela Green, Claire Frances Friedman, Rachel N. Grisham, Roisin Eilish O'Cearbhaill, Tiffany A. Troso-Sandoval, Seth M. Cohen, Stuart M. Lichtman, Jason A. Konner, Martee Leigh Hensley, Dmitriy Zamarin, Carol Aghajanian, Vicky Makker
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281945285